标题
New Strategies for Medical Management of Castration-Resistant Prostate Cancer
作者
关键词
-
出版物
ONCOLOGY
Volume 80, Issue 1-2, Pages 1-11
出版商
S. Karger AG
发表日期
2011-05-17
DOI
10.1159/000323495
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
- (2010) Jean-Christophe Eymard et al. BJU INTERNATIONAL
- A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy
- (2010) P. Mathew et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
- (2010) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Studies of Drug Combinations
- (2010) Jaap Verweij et al. JOURNAL OF CLINICAL ONCOLOGY
- [18F]Fluorodeoxyglucose Positron Emission Tomography in the Initial Staging of Squamous Cell Carcinoma of the Head and Neck: Promise, Evidence, and Reality
- (2010) Jonas A. de Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
- (2010) Anders Olsson et al. Molecular Cancer
- VEGF Inhibitors and Prostate Cancer Therapy
- (2010) Jeanny Aragon-Ching et al. Current Molecular Pharmacology
- Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer
- (2009) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
- (2009) O Bratt et al. BRITISH JOURNAL OF CANCER
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
- (2009) Quincy Siu-Chung Chu EXPERT OPINION ON BIOLOGICAL THERAPY
- Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line
- (2009) Gemma Marcias et al. HUMAN MUTATION
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer
- (2009) William L. Dahut et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer
- (2008) A. Hussain et al. ANNALS OF ONCOLOGY
- Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
- (2008) D. R. Berthold et al. ANNALS OF ONCOLOGY
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
- (2008) X. Pivot et al. ANNALS OF ONCOLOGY
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells
- (2008) B KARABULUT et al. CELL BIOLOGY INTERNATIONAL
- A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
- (2008) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Targeting CYP17: established and novel approaches in prostate cancer
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
- (2008) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- (2008) Nicholas D. James et al. EUROPEAN UROLOGY
- Pleiotropic functional properties of androgen receptor mutants in prostate cancer
- (2008) Jean-Pierre Bergerat et al. HUMAN MUTATION
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
- (2008) Orazio Caffo et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now